Jiang Pi | Immunotherapy | Best Researcher Award

Posted on by ScienceFather

Assoc Prof Dr. Jiang Pi | Immunotherapy | Best Researcher Award

Assoc Prof Dr. Jiang Pi, School of Medical Technology, Guangdong Medical University, China

Assoc. Prof. Dr. Jiang Pi appears to be a strong candidate for the Best Researcher Award based on the following qualifications:

Publication profile

Research Excellence:

Dr. Jiang Pi has made significant contributions to the fields of biomaterials, nanotechnology, and targeted drug delivery, particularly in developing innovative therapies for tuberculosis and cancer. His work has resulted in numerous high-impact publications in leading journals, demonstrating a strong research output and expertise.

Recognition and Honors:

 Dr. Jiang has been listed among the world’s top 2% scientists for three consecutive years (2021-2023). This recognition highlights his influence and contribution to his field on a global scale.

Leadership and Editorial Roles:

As Vice Dean at Guangdong Medical University, Dr. Jiang shows leadership in academia. His editorial roles in high-impact journals like Pharmacological Research, Frontiers in Pharmacology, and others reflect his active involvement and recognition in the scientific community.

Postdoctoral and Academic Training:

His extensive training, including a postdoctoral research position at the University of Illinois, Chicago, provides a solid foundation for his research.

Scientific Funding and Projects:

 Dr. Jiang Pi has secured significant research funding, underscoring his capability to lead and manage research projects successfully.

Publication Top Notes  

  • 🦠 Roles of HIF-1α signaling in Mycobacterium tuberculosis infection: New targets for anti-TB therapeutics?
    Authors: Li, C., Wang, J., Xu, J.-F., Pi, J., Zheng, B.
    Source: Biochemical and Biophysical Research Communications, 2024, 711, 149920.
    📚
  • 🌿 Intratracheal Administration of Stem Cell Membrane-Cloaked Naringin-Loaded Biomimetic Nanoparticles Promotes Resolution of Acute Lung Injury
    Authors: Jin, H., Zhao, Y., Yao, Y., Pi, J., Huang, G.
    Source: Antioxidants, 2024, 13(3), 282.
    📚 Cited by: 2
  • 🧠 Exploring Novel Antidepressants Targeting G Protein-Coupled Receptors and Key Membrane Receptors Based on Molecular Structures
    Authors: Yao, H., Wang, X., Chi, J., Pi, J., Xu, J.-F.
    Source: Molecules, 2024, 29(5), 964.
    📚 Cited by: 1
  • 🧬 Zinc Oxide-Selenium Nanoparticles for Inhibiting the Proliferation of Porcine Reproductive and Respiratory Syndrome Virus
    Authors: Xu, Y., Li, Q., Chen, Y., Zhou, L., Liu, J.
    Source: ACS Applied Nano Materials, 2024, 7(4), pp. 3734–3747.
    📚 Cited by: 2
  • 💊 Oral delivery of pH-sensitive nanoparticles loaded Celastrol targeting the inflammatory colons to treat ulcerative colitis
    Authors: Zhao, Y., Yao, Y., Fan, S., Huang, G., Jin, H.
    Source: Journal of Tissue Engineering, 2024, 15.
    📚
  • 🦠 Identification and Validation of Genes Related to Macrophage Polarization and Cell Death Modes Under Mycobacterium tuberculosis Infection
    Authors: Yang, Z., Wang, J., Pi, J., Zhao, Y., Wang, Y.
    Source: Journal of Inflammation Research, 2024, 17, pp. 1397–1411.
    📚
  • 🦠 Macrophage targeted iron oxide nanodecoys augment innate immunological and drug killings for more effective Mycobacterium Tuberculosis clearance
    Authors: Shen, L., Liao, K., Yang, E., Xu, J.-F., Pi, J.
    Source: Journal of Nanobiotechnology, 2023, 21(1), 369.
    📚 Cited by: 2
  • 📈 Advances of Long Non-Coding RNAs as Potential Biomarkers for Tuberculosis: New Hope for Diagnosis?
    Authors: Xia, J., Liu, Y., Ma, Y., Xu, J.-F., Pi, J.
    Source: Pharmaceutics, 2023, 15(8), 2096.
    📚 Cited by: 3

Conclusion

Dr. Jiang Pi’s profile demonstrates the qualifications, recognition, and impact necessary for consideration in the Best Researcher Award.

Zhila Taherzadeh | Immunopharmacology | Academic Impactful Innovation Award

Posted on by ScienceFather

Mrs. Zhila Taherzadeh | Immunopharmacology | Academic Impactful Innovation Award

Professor, Mashhad University of Medical Sciences, Iran

Dr. Zhila Taherzadeh is an Associate Professor of Clinical Pharmacology and Physiology at Mashhad University of Medical Sciences, Iran. She holds a Pharm.D. from the School of Pharmacy, Mashhad University of Medical Sciences, and earned her Ph.D. from the Academic Medical Center in Amsterdam, Netherlands. Her research focuses on targeted drug delivery, inflammation, and hypertension, with a special interest in traditional plant medicines.

Profile

Google Scholar

📚 Education

Dr. Zhila Taherzadeh completed her Pharm.D. at the School of Pharmacy, Mashhad University of Medical Sciences, Iran, in 1996. She pursued her Ph.D. at the Academic Medical Center in Amsterdam, Netherlands, from 2005 to 2011, specializing in Biomedical Engineering & Physics and Internal Medicine.

💼 Experience

Currently affiliated with Mashhad University of Medical Sciences, Dr. Taherzadeh serves as an Associate Professor in the Departments of Pharmacodynamics & Toxicology and Clinical Pharmacology. She holds administrative roles as Director of Educational Development Office (EDO) and Pharmacy Skills Laboratory at the university.

🔬 Research Interests

Dr. Taherzadeh’s research interests include clinical studies on traditional plant medicines, inflammation, immune system polarization, educational research, and hypertension-related vascular function and structure.

🏅 Awards

Throughout her career, Dr. Taherzadeh has received several accolades, including the Honor Researcher Student award at the 2nd Iranian Pharm.D. Students Seminar in Mashhad, Iran, in 1995.

📄 Publications

Brewster LM, Perrotta ID, van Montfrans GA. Should women have lower thresholds for hypertension diagnosis and treatment? J Hum Hypertens. 2023 Aug;37(8):753-754. Link

Piranaghl H, et al. The potential therapeutic impact of a topical bacteriophage preparation in treating Pseudomonas aeruginosa-infected burn wounds in mice. Heliyon. 2023;9(7)

Naserifar M, et al. Modified POPI Criteria to Assess the Quality of Prescriptions to Pediatric Patients. Iran J Pediatr. 2023;33(2)

Karizi SR, et al. A randomized, double-blind placebo-controlled add-on trial to assess the efficacy, safety, and anti-atherogenic effect of spirulina platensis in patients with inadequately controlled type 2 diabetes mellitus. Phytother Res. 2023;37(4):1435-1448. Link

Hejazi Y, et al. The Effect of Practice Prescription E-Learning System on Learning and Motivation of Pharmacy Students. Technol Knowl Learn. 2023. Link